✦ LIBER ✦

209 POSTER An open-label, multicenter, phase 1/2 study of AT-101 in combination with docetaxel and prednisone in men with hormone refractory prostate cancer

✍ Scribed by G. MacVicar; F.A. Greco; J. Reeves; B. Curti; B. Poiesz; B. Somer; K. Brill; L. Leopold

Book ID: 119599364
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 79 KB
Volume: 6
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(08)72141-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase 2 study of carboplatin plus doce

A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel

✍ Robert W. Ross; Tomasz M. Beer; Susanna Jacobus; Glenn J. Bubley; Mary-Ellen Tap 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB 👁 2 views

## Abstract ## BACKGROUND. Prostate cancer is the second leading cause of cancer mortality among men in the U.S. To the authors' knowledge, there is no proven, effective, second‐line therapy for docetaxel‐refractory disease. Recent data suggest that platinum salts may be effective when combined wi

211 POSTER Results of a phase II study o

211 POSTER Results of a phase II study of picoplatin with docetaxel and prednisone in chemotherapy-naive patients with metastatic hormone refractory prostate cancer (HRPC)

✍ R. DeJager; L. Roman; N. Lopatkin; P. Karlov; H.B. Breitz; R. Earhart 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Early results of a multicenter phase 2 s

Early results of a multicenter phase 2 study: Weekly docetaxel and intermittent estramustin as combination chemotherapy in patients with hormone-refractory prostate cancer (HRPC)

✍ U. Steiner; K. Miller; S. Machtens; B. Backhaus; M. Siegsmund 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 226 KB

The Canadian Uro-Oncology Group multicen

The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone

✍ Fred Saad; Dean Ruether; Scott Ernst; Scott North; Tina Cheng; Paul Perrotte; Pi 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB

Phase II study of cytarabine in men with

Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers

✍ Neesha C. Dhani; Urban Emmenegger; Laurie Adams; Jan Jongstra; Ian F. Tannock; S 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 191 KB

704 POSTER A phase I dose escalation and

704 POSTER A phase I dose escalation and pharmacokinetic study of BIBF 1120, a novel tyrosine kinase inhibitor against VEGFR, PDGFR and FGFR, in combination with docetaxel in advanced chemonaive hormone refractory prostate cancer patients (HRPC)

✍ E. Raymond; F. Goldwasser; G. Bousquet; C. Le Tourneau; S. Faivre; H. de-Montser 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 64 KB